The proposed national pharmaceuticals policy that seeks to control the prices of drugs will only end up devaluing the country’s pharma sector, Biocon Limited said on Thursday.The government was committing its “biggest mistake” by “not listening” to the industry ahead of finalising the matter, lamented Kiran Mazumdar-Shaw, chairperson and managing director of the country’s leading bio-pharmaceutical company.Speaking at the sidelines of TieCon Chennai 2011, she said the government should, instead of introducing a policy “which will not serve any purpose”, strive towards formulating and passing a Bill that would ensure healthcare coverage for all citizens.“Currently, it (healthcare coverage) is a self-pay market. There is a realisation that we need a national healthcare system. There is a Bill on this coming, but we need to do (implement) it fast,” added the boss of the 1978-founded Bangalore-based firm.Shaw said she hoped the government did not go ahead with the pharmaceuticals policy. “It is a retrograde step,” she opined. “This knee-jerk to controlling FDI (foreign direct investment) in the pharma sector is draconian. It is detrimental to the interests of the industry.”The 57-year-old entrepreneur noted that the price control era had, in the past, shown its capability to stop the production of essential drugs. “There are enough bulk purchasing and tendering mechanisms that will keep prices down. The government should rather spell out a Bill to ensure that people enjoy the benefits of healthcare coverage,” she said.Shaw said the government has not listened to the pharma industry on the policy; what’s more, a single ministry is taking all the decision. There is no proper feedback mechanism for any policy the government introduces. Nobody knows whether they are working well . A classic exampleis the NREGA,” she said.The other example, Shaw noted, was repeated increase in the interest rate. “This is supposed to control inflation. But what it is happening is the opposite. There is food shortage,” she added.
Subscribe to:
Post Comments (Atom)
Superhit News
-
US health regulator USFDA has issued a warning letter to German drug firm Fresenius Kabi AG for lapses at its drug manufacturing fac...
-
Goods and Service Tax (GST) is high on the agenda for the new government and its rollout is a priority. GST will benefit the Indian pharma...
-
Rib-X Pharmaceuticals, Inc. announced today the signature of an exclusive worldwide research collaboration agreement and option for license ...
-
Physiomics: Reports difficult trading but highlights growing interest from big pharmaceutical groupsPhysiomics ( LON:PYC ) said that trading conditions were difficult in the six months ended 31 December 2010, but it believes it is in a be...
-
Hindusthan National Glass and Industries Ltd is expected to finalize a strategic overseas acquisition in the pharmaceuticals space in the n...
-
The Minister of State (Health and Family Welfare), Sh Ashwini Kumar Choubey through a written reply in the Lok Sabha informed about th...
-
India's Central Drugs Standard Control Organization (CDSCO) has suspended the manufacturing of eye drops at the Chennai-based firm after...
-
The government is hoping to see the implementation of the track and trace system for domestic and export supply chain in another one y...
-
Diclofenac injection is a painkiller which is manufactured by Themis Medicare Ltd and marketed by Novartis India under the brand name ...
-
Amylin Pharmaceuticals, Inc. AMLN +16.15% and Alkermes plc ALKS +4.61% today announced that the U.S. Food and Drug Administration (FDA) has ...
No comments:
Post a Comment